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1. Introduction
The history of immunotherapy of cancer dates back to 1890s when New York surgeon William
Coley used Streptococcus and Serratia bacterial extracts to treat cancer. Up to the mid-1930s
‘Coley’s mixed toxins,’’ were used to treat various tumors. Better understanding of the human
immune system led to the identification of a number of tumor-associated antigens (TAAs) in
the 1980s [1] and development of various immunotherapeutic approaches. Of particular
relevance to melanoma immunotherapy was the identification of various antigens expressed
specifically in melanocytes and, respectively, in the majority of melanomas. These melanoma-
associated antigens include tyrosinase (Tyr), a key enzyme in melanin biosynthesis, tyrosinase-
related proteins 1 and 2 (TRP1, TRP2), gp100 (aka pmel17), Melan-a, and MART1. These and
several other melanoma-associated antigens formed the basis for the immunologic targeting
of the tumor. Up to date, multiple peptide, dendritic cell, adjuvant, lymphocyte, antibody,
DNA and virus-based strategies were tested in pre-clinical and clinical studies with varying
degrees of success. In recent years, identification of the specific antigenic MHC class I epitopes,
advancements in genetic engineering, gene delivery, and cell-based therapeutic approaches
allowed development of the novel melanoma-targeting immuno-therapeutics.
2. Genetic engineering of antigen-specific T cells
2.1. Recombinant T cell receptors
Identification of the tumor-reactive T cells among a population of the tumor-infiltrating
lymphocytes led to the development of the T cell-based therapies, particularly to the strategy
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known as adoptive T cells transfer. This strategy is based on the isolation of the tumor-
infiltrating lymphocytes following analysis of their ability to target tumor cells and clonal
expansion of tumor-reactive T cells via stimulation of cell proliferation with anti-CD3 and
antiCD28 antibodies in the presence of IL-2. Upon obtaining a large quantity (> 108 cells), these
cells are infused back to a tumor-bearing patient along with the lymphodepleting chemother‐
apy to temporary knock down circulating immunocytes and repetitive administration of the
IL-2 (Fig. 1).
Figure 1. Clinical application of the T cell-mediated tumor immunotherapy. Diagram on the top depicts application of
the Tumor-Infiltrating Lymphocytes (TILs). Diagram on the bottom illustrates application of the genetically engineered
(TCR and CAR-modified) T cells.
Presently, 87 clinical trials using TIL are completed or on-going. These clinical trials are aimed
at treatment of multiple cancers including: Malignant Melanoma, Nasopharyngeal Carcinoma,
Hepatocellular Carcinoma, Breast Carcinoma, Leukemia, Lymphoma, Multiple Myeloma,
Plasma Cell Neoplasm, Kidney Cancer, Metastatic Colorectal Cancer, Metastatic Gastric
Cancer, Metastatic Pancreatic Cancer, Metastatic Hepatocellular Carcinoma, Cervical Cancer,
Oropharyngeal Cancer, Vaginal Cancer, Anal Cancer, Penile Cancer, Non-Small Cell Lung
Cancer, Brain and Central Nervous System Tumors. Several completed clinical trials on
malignant melanoma clearly demonstrated that infusing TILs along with IL-2 and pre-
conditioning with reduced-intensity circulating lymphocyte-depleting chemotherapy medi‐
ates tumor-targeting immune response in up to 50% of patients [2]. The highest response rate
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up to 70 % with up to 30% complete remission lasting for up to 3 years was reported when
radiation sensitization was used in conjunction with the transfer of the tumor-reactive TILs.
Despite the success of the pioneering studies at the Surgery Branch of the US National Cancer
Institute and the consequent clinical trials, this approach, although holding much promise in
treating melanoma, is facing several challenges that limit broad application of the TIL-based
immunotherapy. As TILs are isolated from resected tumors, the first and foremost requirement
is the eligibility for surgery, which should be conducted, preferably, in the facility equipped
for the isolation of TILs, identification and expansion of the tumor-reactive T cells. Ex vivo
stimulation and propagation of TILs to large quantities required for the effective immuno‐
therapy is time-consuming, labor-retaining, and expensive. Although recent clinical studies
showed that infusion of the minimally cultured TILs without pre-selection for tumor reactivity
provide a rather high response rate [3], the search for a better melanoma-targeting strategy is
on-going.
Nevertheless, isolation of the individual melanoma-reactive T cell clones allowed the devel‐
opment of another immunotherapeutic approach – generation of the T cells expressing
recombinant antigen specific T cell receptors (TCRs). TCRs are members of the immunoglo‐
bulin family proteins. Each TCR consists of 2 different membrane-anchored chains that are
joined by the disulfide bridges to form heterodimer. About 95% of the T cells are characterized
by the expression of the α and β chains, whereas the remaining 5% express γ and δ chains.
Respectively, T cells expressing these receptors are often referred to as α/β and γ/δ T cells. Each
chain is comprised of the variable and constant regions. The variable domain of both α- and
β-chains have three hypervariable regions also known as complementarity determining
regions (CDR), however, the β-chain has an additional area of hypervariability that is not
involved in antigen binding. TCR α and γ chains are generated within T cells by VJ recombi‐
nation, whereas β and δ chains by the V(D)J recombination. Currently, the majority of the TILs
selected for the ability to target tumors are α/β T cells expressing respective TCR chains that
determine T cell specificity to an antigenic peptides presented by the major histocompatability
complex (MHC) proteins. Therefore, it was proposed that sequences encoding tumor antigen
recognizing TCR chains can be obtained from tumor-reactive T cells and then used for the gene
transfer into patient-derived lymphocytes, thereby creating large quantities of tumor-reactive
T cells. The first TCRs specific to melanocytic antigens MART-1 and gp-100 were cloned in
1990s. Pioneering clinical studies using human peripheral blood lymphocytes transduced with
these TCRs demonstrated melanoma regression in lymphodepleted patients [4] (Fig. 1).
Although these and other initial clinical studies demonstrated a feasibility of the recombinant
T cells-based approach, they also revealed multiple challenges. For example, the ability of
recombinant TCR chains to interact and pair with the endogenous chains could lead to the
generation of 4 different TCRs in a single cell (Fig. 2). Chain misparing decreases the expression
of the function, tumor-reactive TCRs and therefore reduces T cell-mediated tumor targeting.
To overcome misparing, several strategies were proposed. Recent pre-clinical and clinical
studies demonstrated that replacement of the human TCR constant region with murine
counterpart reduced misparing and allowed enhanced expression of the functional TCRs and
improved T cell functional activity [5]. It was also reported that targeted mutagenesis and
generation of the additional cystein residues in recombinant α and β chains permitted stronger
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pairing of these chains, higher expression of functional TCRs and improved T cell function [6,
7]. Recent studies also showed that targeting of the endogenous chains by siRNA allows higher
expression of the functional recombinant TCR. Of particular interest is the proposed approach
to encode siRNA along with the TCR chains to concurrently express recombinant and inhibit
translation of the endogenous chains [8]. Protein engineering was also employed to improve
pairing of the recombinant chains. Thus, substitution of specific amino acids within constant
regions of the antigen-specific TCRs supported paring and enhanced functional activity of
these receptors [9]. It remains to be determined which of these recombinant DNA-based
methods will provide better targeting of melanoma (Fig. 2). Nevertheless, recent studies using
chimeric murine-human hybrid highly avid tyrosinase-specific TCR demonstrated a favorable
clinical outcome [10].
Figure 2. Strategies aimed at the improvement of the recombinant TCR pairing. Expression of the recombinant TCR
may lead to the generation of 4 different TCRs within a cell (center). Different strategies designed to improve tumor-
specific recombinant TCR pairing and activity include: generation of hybrid molecules containing the constant region
from murine TCR, addition of disulfide bonds, alteration of the amino acid sequence within the TCR chains, and siRNA-
mediated inhibition of the endogenous TCR gene expression (see text for details).
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It is apparent that both α and β chains of the antigen-specific TCR should be expressed in each
individual T cell. To date, internal ribosomal entry site (IRES) elements [11], double promoters
[12], or co-infection with several viral vectors [13] were used to express several heterologous
proteins in cells. However, these methods have their imperfections. For instance, in IRES-
mediated co-expression, the upstream protein is usually more strongly transcribed than the
downstream protein. Expression of the proteins from two different or biscistronic promoters
or the use of multiples viruses also do not provide equal concurrent expression of multiple
transgenes. A more promising approach involves the use of the self-processing viral peptide
bridges such as 2A or 2A-like peptides described in Picornaviridae [14]. In picornavirus, these
sequences share a highly conservative 18 amino acids motif mediating cleavage between C-
terminal glycine and N-terminal proline of the 2B peptide. At present 2a and 2A-like sequences
are commonly refer to as cis-acting hydrolase elements that allows ribosome skipping and
cellular expression of multiple, discrete proteins in essentially equimolar quantities derived
from a single ORF. To ensure concurrent expression of both α and β chains of the transgenic
TCR an A2 sequence is most commonly used for quantitative co-expression of these heterol‐
ogous proteins.
Transfer of the recombinant TCR genes into the T cells is another somewhat limiting factor for
the broad application of the genetically engineered T cells for melanoma immuno-targeting.
Currently, for human applications, a gene transfer platform that can mediate stable transfer
of the TCR genes is retroviral system [15]. Lentiviral vectors and transposons were also tested
[16, 17]. Use of retroviruses provided several advantages including a rather high infectivity
and rapid integration of the transgene into host genome. With multiple vector backbones, virus
packaging cell lines, and well-established GMP protocols, a retroviral system offers relative
simplicity of viral vector construction and production of viruses. Since retroviruses can infect
only dividing cells, stimulation of the T cell proliferation must be done prior to the gene
transfer. Also, these viruses have limited capacity for the packaging. For instance, high virus
titers cannot be obtained with larger retroviral vectors. Although an average size of a viral
vector encoding typical α/β TCR is around 7 kb, this limits possible alternative approaches
such as inclusion of various regulatory elements or another transgenes that may enhance T
cell activation. Use of the viral system also presents certain safety concerns relevant to the
random integration of the transgenes into the host genome that may result in the activation of
oncogenes or inactivation of tumor suppressors. This may lead to the various adverse invents
including development of a lymphoproliferative disease resembling leukemia due, in part, to
the integration of the retroviral gene transfer vehicle near an oncogene [18, 19]. Thus far, the
development of lymphoma-like symptoms has not been reported in patients treated with
recombinant T cells. It is also essential to note that production of the TCR-encoding cGMP
virus substantially increases the cost of the treatment with recombinant T cells. On the contrary
to the retrovirus-based gene transfer, lentiviruses can infect non-dividing cells and therefore
can be used for the gene transfer into quiescent T cells. Although “safe” lentiviral systems are
developed to minimize the chance of producing replication-competent virus (eg. ViaraSafe
from Cell Biolabs), transduction of patient-derived T cells for the adoptive transfer will always
present some degree of risk.
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Besides viral approaches, non-viral gene transfer may also be used for the expression of the
TCRs in T cells. Recently, a Sleeping Beauty Transposon System was tested for the transduction
of the T cells [17]. Sleeping Beauty Transposon System consists of two components - the
transposon, composed of inverted terminal repeat sequences (IRs) with desired genetic
material in between, and a SB transposase enzyme. Most recently, a number of IRs and
hyperactive transposases with increasing enzymatic activities were developed to mediate
transposition of transposon-encoding proteins into the genomic DNA [20]. Although trans‐
position of SB transposons appears to be unregulated, it has certain advantages over viral based
approaches. For instance, expression of transgenes, TCRs in particular, could be regulated by
specific promoters that provide either T cell specific expression (eg. CD3 promoter; [21, 22]),
or high level of expression (eg. elongation factor 1 promoter; [23,24]. Promoters may also be
selected for further specific applications (discussed below). On the contrary to the viral gene
transfer, non-viral systems also permit significantly simpler production of the cGMP-grade
material (plasmid DNA) and lesser safety testing. Up to date, the Sleeping Beauty transposon-
mediated approach was shown to mediate a long-term stable integration of the T-cell receptor
genes targeting melanoma-derived antigen, MART-1, in laboratory settings (Fig. 3b). This
system provided 50% efficiency of the TCR integration into the genome of the T cells and
sustained functional reactivity of lymphocytes to the antigen-positive melanoma [25].
Other non-viral strategies could be useful in genetic engineering of the T cells. For example,
integrase-mediated insertion of the genetic material may provide stable, site-directed integra‐
tion of the transgenes (TCRs) into T cell genome. This strategy involves integrase from the
Streptomyces phage ΦC31 that catalyzes unidirectional recombination between attP motifs in
phage and attB sites in bacterial genomes. Usually attP and attB sites are cleaved and joined
to each other, generating two hybrid sequences (attL and attR) that flank the integrated phage
genome. However, ΦC31 integrase can also recognize several endogenous sequences in
eukaryotic chromosomes as attP sites and integrate attB-bearing transgenes into them (Fig.
3c). Such pseudo attP sites were found in every mammalian genome with more than 100 ΦC31
integration sites identified in human cells. Thus far, only three preferred sites located in human
Xq22.1, 8p22, 19q13.31 loci are commonly used by this enzyme [26, 27]. Therefore, ΦC31-
integrase-based system is somewhat similar to the SB transposone system (Fig. 3b, c). Yet, it
provides better specificity of the transgene integration. We recently tested whether ΦC31 can
efficiently integrate transgenes into the T cells. Our initial data using GFP-encoding reporter
plasmid with short (34bp) attB site demonstrated that nucleofection reaction provides rather
efficient transduction of the transgene and ΦC31 integrase-encoding plasmids into T cells (Fig.
4a) and stable, integrase-dependent insertion of the reporter into both CD4+ and CD8+ T cells
(Fig. 4b). Transduction of the T cells with tyrosinase-specific TCR (described in 10) ligated into
the attB-harboring mammalian expression vector also resulted in the sustained expression of
this melanoma-specific TCR and the ability of the T cells to target antigen-positive melanoma
cells in vitro (Fig. 4c)
Collectively, viral and non-viral strategies for the genetic engineering of the T cells expressing
melanoma-specific TCRs are suitable for the ex vivo production of large quantities (more than
108 cells) of the tumor-specific T cells that can be used for the adoptive T cell transfer. However,
clinical utility of the non-viral approaches remains to be elucidated. In spite of T cell trans‐
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duction strategy, it is clear that the ability to generate melanoma-specific recombinant T cell
receptors allowed significant advancement in the development of the clinically-applicable
TCR-based approach for melanoma immunotherapy. Its primary advantages are in the use of
Figure 3. Schematic diagram depicting genetic engineering of the tumor-targeting T cells expressing recombinant TCR.
Diagrams depict generation of the recombinant T cells via (a) retrovirus-mediated gene transfer, (b) Sleeping Beauty trans‐
poson-mediated gene transposition, and (c) ΦC31 integrase-mediated gene insertion (see text for details).
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a natural and a rather well-understood mechanism of the T cell function and the ability to
select/generate multiple melanoma-reactive TCRs that can be used alone or in combination.
Currently, several melanoma-targeting TCRs specific to tyrosinase, MART-1, and gp100 were
cloned. One can envision generation of TCR-encoding cDNA banks that could be utilized for
the generation of different melanoma-reacting T cells from the pool of patient-derived T cells
to target several TAAs. However, this strategy has several disadvantages including restriction
of specific TCRs to one HLA type, dependence from the expression and presentation of an
antigen, limited intracellular signaling from the recombinant α/β TCRs, misparing of TCR
chains, and the inability to target non-protein tumor antigens.
At present time, about 20 clinical studies involving melanoma-specific T cells expressing
recombinant TCR were conducted in US alone (some of them reviewed in [28]). The result of
some of the completed trials opened new perspectives for the improvement of the TCR-based
strategies. For instance, adoptive transfer of the T cells genetically engineered to express highly
avid MART-1-specific TCR has achieved objective clinical responses in a 13% of treated
patients [29]. Analysis of CTL-resistant tumor cell revealed that these resistant clones exhibited
hyperactivation of the NF-κB survival pathway and overexpression of the antiapoptotic Bcl-2,
Bcl-x, Bcl-xL, and Mcl-1 genes [30]. These studies suggest that sensitivity of melanoma to the
recombinant T cells could be increased by the pharmacological inhibition of the NF-κB
pathway and/or Bcl-2 family members. Multiple investigative studies are on-going to further
improve recombinant TCR-based approach.
Figure 4. ΦC31 integrase-mediated genetic modification of the T cells. (a) Example showing typical nucleofection re‐
action of the reporter gene (GFP) into freshly isolated T cells 24 hours post Nucleofection (representative FACS pro‐
files). (b) Analysis of the GFP expression after Nucleofection of the T cells in the presence of absence of the ΦC31
integrase-encoding plasmid (representative profiles and the direct fluorescent microscopy) 3 and 14 days after Nucle‐
ofection. (c) FACS-based analysis of the CTL activity of the recombinant T cells generated to express tyrosinase-specific
TCR against human melanoma in vitro (representative profile). Times and percentages are indicated in the panels;
Shaded Profiles – GFP-positive cells (see text for details).
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2.2. Chimeric antigen receptors
Independently, an alternative approach involving recombinant DNA technology was devel‐
oped to generate tumor-targeting T cells. It utilizes fusion of the variable chain of the tumor-
antigen-specific antibody, TCR constant region, and intracellular signaling domains. Initially,
these structures were called T-bodies [31]. They are comprise of the single-chain antibody (sFv),
TCR transmembrane domain and the intracellular signaling domain of the TCR-ζ. One of the
first tumor associated antigens targeted by T cells expressing T-bodies was erbB2 (HER2/neu)
receptor that is over-expressed in multiple cancers [32]. Later, a more general term – chimeric
antigen receptors or CARs emerged. As compared to the TCRs, CARs allow overcoming
dependency on HLA type, antigen presentation, and restricted intracellular signaling of the
recombinant α/β TCRs. Initial studies with T-bodies (and recombinant TCRs) demonstrated a
rather short lifespan of the engineered T cells and the inability of the recombinant receptors
to fully support persistence of the T cell. To address this issue, several studies were conducted
to identify the most potent CAR structures by testing several signaling molecules involved in
T cell activation (Fig. 5). It was demonstrated that fusion of TCR-ζ with the intracellular domain
of CD28 can augment cytokine production by CAR-expressing T cells upon encountering
antigen and enhance antitumor efficacy [33]. Inclusion of CD134 (OX-40) into CAR structure
also led to the elevated tumoricidal activity of the recombinant T cells [34]. Comparative
analysis of the different CARs comprised of TCR-ζ signal transduction domain, CD28 and/or
CD137 (4-1BB) intracellular domains demonstrated that addition of the CD137 supports T cell
function to a greater extent as compared to other constructs [35]. Collectively, addition of these
signaling domains to the CAR structure allowed overcoming (to certain extent) inefficient
effector function and anergic status of the T cells.
Figure 5. Recombinant TCR and CAR structures. (a) Diagram depicting recombinant TCR structure. (b) Diagram illus‐
trating molecular interactions involved in TCR-mediated pro-proliferation and pro-survival intracellular signaling in‐
cluding engagement of the CD28, CD3, and CD137 (4-1BB). (c) Diagram depicting recombinant CAR structure with
CD3ξ, CD137 (4-1BB), and CD28 signaling domains (see text for details).
As recognition of target cells by CAR depends on the antibody, CARs can recognize not only
polypeptides but also non-protein molecules such as tumor-associated glycolipids and
carbohydrates. However, antibody-mediated binding require surface expression of an antigen
and strict selection of TAAs to avoid autoimmune side effects. Also, use of the mouse mono‐
clonal antibody sequences in CAR design may lead to the unwanted immune recognition of
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the CAR-expressing T cells and limit long-term clinical use [36, 37]. Nevertheless, existence of
a large number of the tumor antigen-specific antibodies and robust anti-tumor response by
CAR-expressing T cells suggest great clinical utility of these recombinant molecules. Currently,
in US alone there are 18 clinical trials aimed at treatment of various malignancies with CAR-
engineered leukocytes, with 16 trials in the recruitment phase. Eight of them are aimed at
targeting different B cell malignancies with anti-CD19-CAR. Three trials are intended to test
HER2-specific CAR-modified T cells for the treatment of sarcoma, glioblastoma, and advanced
Her2-positive lung malignancy.
With regard to melanoma, several CAR designs were tested for the ability to target this
malignancy. Thus, recent studies demonstrated that treatment of melanoma xenografts in
nude mice using engineered T cells expressing tandem CAR (CD28/TCRζ) specific to ganglio‐
side GD3 with IL2 supplementation led to complete remissions of the established tumors in
50 % of treated animals [38]. As GD3 is often over-expressed in melanoma, this approach could
be potent in eliminating melanoma in human patients.
Another attractive target for the CAR-mediated T cell therapy for melanoma is a high molec‐
ular weight melanoma-associated antigen (HMW-MAA) encoded by CSPG4 gene. This is a
cell-surface proteoglycan expressed on more than 90% of the tumors. Recent studies on
targeting of this antigen using CAR that is comprised of the anti- HMW-MAA antibody chain
and intracellular signaling domains of the CD28, CD137, and CD3ζ demonstrated that T cell
genetically modified to express this CAR were cytolytic to the HMW-MAA–positive melano‐
ma cells, produced cytokine and proliferate in vitro [39]. The potential clinical utility of the
CAR-mediated HMW-MAA targeting was emphasized by another recent animal study [40].
Analysis of a few human melanoma biopsies revealed the presence of less than 2% of specific
tumor cells co-expressing CD20 and HMW-MAA. Implantation of tumors containing these
CD20+ HMW-MAA+ cells into immuno-deficient mice resulted in a rapid growth of tumors.
Targeting of these pre-established lesions with T cells expressing either CD20 or HMW-MAA-
directed CAR showed elimination of lesions in nearly 90% of treated animals. CD20-specific
engineered T cells were unable to eradicated melanoma lesions artificially expressing CD20
suggesting that native expression of the antigen is required for effective targeting. These
studies provided additional evidence that direction of the T cells toward HMW-MAA via
genetic engineering can permit effective elimination of tumor lesions.
As progression of most tumors including melanoma depends on the microenvironment, T-cell
mediated targeting of the microenvironmental components could also be a viable strategy for
melanoma immunotherapy. Particularly, tumor survival was shown to be dependent on the
de novo formation of the intratumoral blood vessels characterised by high levels of the vascular
endothelial growth factor receptor 2 (VEGFR2/KDR). Also, a number of studies associated high
levels of VEGFR2 expression with various tumor stroma cells including subsets of macro‐
phages, immature monocytes, immature dendritic cells and immuno-suppressive CD4+CD25+
regulatory T cells (Treg) [41-46]. Therefore, it was suggested that targeting of VEGFR2 –
positive cells in tumor stroma may provide clinical benefits and tumor regression. In support
of this notion, recent studies demonstrated that the direction of the T cells toward VEGFR-2
via CAR provide an effective means to eliminate pre-established experimental melanoma.
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Thus, using an animal model, it was shown that after systemic transplantation, anti–VEGFR-2
CAR and IL-12–co-transduced T cells infiltrated the tumors, expanded and persisted within
tumor mass leading to tumor regression [47]. The anti-tumor effect was dependent on targeting
of IL-12–responsive host cells via activation of anti–VEGFR-2 CAR-T cells and release of IL-12.
Based on this data, one clinical trial aimed at the assessment of safety and effectiveness of cell
therapy was initiated to treat recurrent and relapsed cancer by using anti-VEGFR2 CAR-
modified T cells.
Presently, there is an accumulating body of evidence suggesting clinical utility of the T cell
genetically engineered to express melanoma antigen-specific CARs. It is likely that in the near
future CAR-mediated targeting of different melanoma antigens will evolve into general
practice of cancer immunotherapy.
3. DNA vaccination
Another immunotherapeutic approach directly relevant to recombinant DNA is genetic or
DNA vaccination. The original idea of DNA vaccination emanated from the observations that
intramuscular injection of DNA encoding influenza A virus protein resulted in the robust
activation of the immune responses that protected the host from viral challenge [48]. Generally,
DNA-mediated activation of immune response involves multiple processes. First, plasmid
DNA should be delivered intracellularly and expressed in the host cells. Next, in most of cases
the antigen has to be secreted from the cells and picked up by the dendritic cells (DC), processed
and presented in the context of the MHC class II to the CD4+ T helper (Th) cells. Alternatively,
if the antigen is expressed directly in the DCs, it could be processed intracellularly and
presented via MHC class I molecules, leading to the activation of the CD8+ T cells and induction
of the cytotoxic immune responses. Initial studies on DNA vaccination were carried out using
an intramuscular route of vaccine administration (Fig. 6). This allowed high levels of antigen
expression and secretion from the elongated muscle cells into perimysium, the resident site of
the intramuscular DCs. Later, DNA vaccination through the skin was suggested to be superior
over the intramuscular route. Skin has evolved as a barrier to prevent the entry of pathogens,
with efficient immune surveillance complex including Langerhans cells, dendritic cells,
lymphocytes, and other leukocytes. Skin is also rich in lymphatic vasculature network that
provides an efficient route for DC and T cell trafficking. Depending on the physical methods
of into-skin DNA delivery, DNA-based vaccines can be targeted to specific locations in the
skin [49].
The DNA vaccination approach has several advantages over other types of vaccinations: (i)
multiple expression vectors coding for different antigen and co-stimulatory molecules can be
concurrently delivered into the skin (or the muscle); (ii) the use of cell-type-specific promoters
can provide specificity of protein expression; (iii) protein expression from designed plasmids
can be controlled by inducible promoters, the use of ubiquitous chromatin opening elements
(UCOE), or chemically (e.g. sodium butyrate). Also of note is the relative simplicity and
inexpensiveness of the cGMP grade DNA vaccine production and pre-clinical testing. These
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attractive characteristics of DNA vaccines have prompted extensive research within the past
10 years.
Multiple studies on pre-clinical animal models of melanoma and other cancers have been
conducted. Studies on the canine model of aggressive and metastatic melanoma (stages II-IV)
demonstrated that xenogeneic vaccination of dogs with DNA vaccine coding for human
tyrosinase led to an excellent clinical response in the majority of vaccinated dogs. A long-term
survival of dogs with advanced stage IV disease with bulky lung metastases (on average 400
days) was observed [50]. Vaccinated dogs with stage II/III disease also had long-term survivals
(on average 500 days) with no evidence of melanoma on necropsy. Overall, median survival
time for all treated dogs was 389 days. Another canine model study [51] showed that xenoge‐
neic DNA vaccination induces melanoma-specific antibody response, which coincides with
observed clinical responses. As a result, in 2010 Merial, an animal health company has gained
full-licensure from the U.S. Department of Agriculture (USDA) for ONCEPT™ Canine
Figure 6. Intramuscular and Intradermal DNA vaccination. Intramuscular and intradermal sites are used for DNA vacci‐
nation. The former allows high level of antigen (Ag) expression in muscle cells and MHC class II Ag processing and
presentation whereas the latter permits expression of the Ag in the Antigen-Presenting Cells (APC) and direct presen‐
tation of the antigenic peptides to the CD8+ cytotoxic T cells (see text for details).
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Melanoma DNA Vaccine. Up to date, ONCEPT is the first and only USDA-approved thera‐
peutic vaccine for the treatment of cancer in either animals or humans. (The first DNA vaccine
was licensed by the USDA in 2005 for prevention of West Nile virus infection in horses).
However, presently only a few human clinical trials on DNA vaccination were conducted. One
of such study, aimed at the evaluation of the immune response in patients with hormone-
refractory prostate cancer showed that DNA vaccination with a prostate-specific antigen (PSA)
encoding plasmid given with GM-CSF and IL-2 is safe in doses of up to 900 μg, and that the
vaccination can induce cellular and humoral immune responses [52].
Similar to the reference above canine studies, DNA vaccines were shown to be effective in
mouse melanoma models when mice were vaccinated with heterologous DNA encoding
human melanoma-associated antigen gp-100 [53]. This vaccination regimen was augmented
by the GM-CSF and was most effective in the prophylactic setting. It was also effective in
suppressing pre-established melanoma. However, vaccinations with autologous mouse
melanoma antigens were less successful. Nevertheless, the relative simplicity of modifying
recombinant DNA allowed testing of various genetic alterations aimed at breaking the
immunologic tolerance and enhancing immune responses to DNA vaccines. For example,
concurrent vaccination with DNA encoding several melanoma-specific epitopes can be used.
This approach was tested in several studies with different degree of success. As a result,
vaccination of mice with gp10025–33 and TRP-2181–188 encoding minigene was effective in
preventing melanoma development [54]. As many of the melanoma MHC class I epitopes were
characterized for melanoma including those derived from tyrosinase, TRP1, TRP2, gp-100,
MART-1, and MC-1R (some of them shared between mouse and human MHC molecules [55],
one can envision generation of an ultimate genetic immunogen capable of targeting several
melanoma-associated antigens.
Recombinant DNA technology has also allowed introduction of immuno-augmentation
sequences into the DNA vaccine composition. Identified universal pan HLA DR helper binding
epitope (PADRE; KXVAAWYLKA) was shown to enhance immunogenicity of both peptide
and DNA vaccines [56, 57]. Other studies demonstrated augmentation of melanoma-specific
immune responses via direct fusion of the DNA vaccine with the VP22 protein of the herpes
simplex virus-1 [58].
Besides introducing immuno-enhancing alteration to the DNA vaccine, other strategies could
be employed to enhance DNA vaccination efficacy including addition of the immuno-
enhancing molecules to vaccine composition, alteration of the microenvironment at vaccine
administration site, and use of the prime-boost immunization regimens. Recent studies
demonstrated that antibody-mediated inhibition of the cytotoxic T lymphocyte antigen 4
(CTLA-4) enhances melanoma-specific immune response. This strategy was recently tested in
treatment of stage III-IV melanoma and the drug (Ipilimumam) was approved by the FDA as
first anti-melanoma immunotherapeutic [59, 60]. CTLA-4 presents its immuno-inhibitory
function during activation of the T cells by the antigen-presenting cells. It also inhibits TCR-
mediated intracellular signaling in activated T cells and down-modulating T cell mediated
immunity. Therefore, it is possible that inhibition of CTLA-4 in conjunction with DNA
vaccination may provide significant enhancement of the vaccine-mediated immune response
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induction. Although providing CTLA-4 inhibiting antibodies like Ipilimumab along with
DNA vaccination is not feasible, other options could be explored. For example, recently
characterized genetically engineered lipocalin (LCN2) exhibits a strong cross-species antago‐
nistic activity to CTLA-4 [61]. It is likely that this molecule could be included into DNA vaccine
composition to enhance DC-mediated activation of the T cells. Other immuno-modulatory
strategies may include addition of CD40 ligand, which was shown to stimulate expression of
maturation markers CD80, CD86 and IL-12 in APC [62, 63] and its ability to activate CD8+ T
cells and increase cell-mediated immunity [64, 65]. Addition of different cytokines and growth
factors including GM-CSF, IL-2, IL12 for stimulation/support of the T cells was also tested in
several studies (as exemplified in preceding paragraphs) and could be further explored.
Alteration of microenvironment via application chemokines to recruit specific sets of the
leukocytes to the vaccine administration site may also provide a favorable milieu for the launch
of the effective DNA-vaccine induced immune response [66, 67]. These and many other
strategies can be proposed; however, the clinical utility of the DNA vaccination combination
with other approaches remains to be determined. Nevertheless, presently in the US alone, 10
clinical studies utilizing xenogenic (mouse) or human DNA vaccines coding for melanoma
associated antigens have been completed. In these trials, tyrosinase, gp75, gp100, and TRP2
were used as antigens. Although most of these studies are already completed, currently no
study results are posted nor are follow-up reports available on patient survival and charac‐
terization of immune response. Nevertheless, DNA vaccination remains to be a promising
modality that could provide cost-effective and generic immunotherapy for patients with
melanoma and other cancers.
4. Other strategies involving recombinant DNA technology
At the present time, almost every immuno-therapeutic approach utilizes recombinant DNA
in one way or another. Understanding of the immuno-regulatory functions of DCs and the
molecular mechanisms involved in the capture, processing and presentation of antigens by
DCs allowed the development of the DC-based vaccines. Initially, in the mid 1990’s, several
pre-clinical and clinical studies were conducted using autologous DCs pulsed with melanoma-
associated antigens. These studies demonstrated that antigen-loaded DC can trigger active
melanoma specific immune responses [68, 69]. However, it became apparent that enforced
expression of the antigens in DC rather than loading of these cells with peptides allows for
presentation of the tumor-derived antigens via MHC class I complex and priming of the CD8+
T cells to elicit cytotoxic immune response. Moreover, to provide DC specific expression of the
antigens, long and short CD11c promoters were characterized and used in several studies [70,
71]. These promoters allow effective and cell type specific expression of the antigens in DCs,
as well as more efficient priming and activation of the T cells in vitro and in vivo. Considering
a necessity of the direct interaction of the DC with T lymphocytes, application of T cell
recruiting chemokines was also explored recently. These pioneering studies demonstrate that
forced expression of the secondary lymphoid chemokine, CCL21, in antigen loaded DCs
enhances their ability to recruit and activate T cells [72, 73]. One clinical phase I clinical trial
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using CCL21 transduced DCs pulsed with MART-1 and gp100 was completed in 2012.
Altogether, a total of 64 clinical trials aimed at targeting of melanoma using dendritic cells are
listed. Thirty nine of them are completed with no reports yet available. The majority of these
trials in some way utilize recombinant DNA technology.
5. Conclusion
During last decade, various melanoma-specific immunotherapeutics that utilize recombinant
DNA have been developed and tested in pre-clinical and clinical studies with varying degrees
of clinical success. Many of these approaches, including recombinant TCRs and CARs, have
already demonstrated promising clinical results, thus providing us with the hope that in the
near future melanoma immunotherapy will become curable for melanoma patients.
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